Embargo Dates and Policy
- Regular Abstract Embargo lifts and publication of regularly submitted abstracts occurs on October 11, 2023, at 8:00 AM ET.
- Late-Breaking Abstract Embargo Lifts on The first day of The Liver Meeting, 2023. Friday, November 10, 2023 at 8:00 AM ET.
All attendees, members of the media, companies, institutions, organizations, universities, investment advisors, and all other individuals, are required to abide by AASLD’s Abstract Embargo Policy governing The Liver Meeting®.
The purpose of the embargo policy is to protect the scientific integrity of the abstract submissions presented at The Liver Meeting. Violation of the embargo policy by the release of information contained in any abstract prior to its embargoed date and time may result in the individual, as well as the employer/affiliated company, institution, organization, etc., being removed from The Liver Meeting, with a potential two-year ban on returning. Authors are responsible for notifying financial and other sponsors about this policy.
An embargo means that the information contained in any abstract is confidential and may not be announced, publicized, or distributed before the embargo date and time except as permitted by this policy. This policy does not prohibit presenters or organizations with accepted abstracts from announcing, publicizing, or distributing abstract titles, authors, and the fact that an abstract has been selected for presentation at The Liver Meeting prior to the remaining content of the abstract being released from the embargo.
When AASLD publishes abstracts on the above-noted date, the specific information which has been published (such as the full text of the abstract and associated images) is released from this embargo policy. Additional information not released at that time, e.g. discussion of the abstract done as part of a scientific presentation or presentation of additional or new information that will be available at the time of the meeting, remains subject to the embargo until it lifts on the first day of the meeting at 8:00 AM local time.
Regular abstracts will be made available on the AASLD website, the TLM app, and the TLMdX platform prior to the start of The Liver Meeting at a date to be determined. Late-breaking abstracts will also be made available in those locations at 8:00 AM local time on the first day of the meeting and will be published in the subsequent February issue of HEPATOLOGY.
Academic institutions, private organizations, and companies with products whose values may be influenced by information contained in an abstract may issue a press release containing information from their abstracts once the information has been released from the embargo.
On a case-by-case basis, AASLD may allow for exceptions to the Abstract Embargo Policy for publicly traded companies which must publicly disclose certain data from its submitted abstract prior to the embargo date to comply with the requirements of the U.S. Securities Exchange Commission (SEC) or a corresponding regulatory body in the country where the company’s stock is traded. However, AASLD requires the company President, General Counsel, or other appropriate officials of a company seeking such an exception to attest in writing to the specific facts in support of the request, including exactly how the securities laws are implicated, with statutory citation(s). General statements of the need to comply with the law will not be considered sufficient. Requests for an exception must be sent to AASLD. AASLD requires a minimum of five (5) days from receipt of the request to evaluate the request. In granting an exception, AASLD may limit the release of information to top-line data from the abstract and requires the company to state in their public disclosure that the complete and final results will be presented at The Liver Meeting. AASLD will also require the inclusion of unreleased and unique data in such a presentation at The Liver Meeting.
AASLD will evaluate exception requests on a case-by-case basis and reserves the right to change the type of presentation (from oral presentation to poster presentation) or remove the abstract from the meeting program if it determines that the released information may substantially detract from the novelty of the presentation.
Public release of a journal article relevant to the abstract will be considered an exception to the Embargo Policy if, at the time of the abstract submission deadline, the decision concerning the manuscript had not been revealed to the authors. Authors are responsible to attempt to coordinate a publication date that abides by the AASLD’s Embargo Policy.
Questions regarding the embargo policy can be addressed to email@example.com